Synopsis

A buzz surrounds medications like Ozempic and Mounjaro, promising rapid weight loss. Approved by the FDA for diabetes treatment, these drugs have ignited widespread interest in their potential for slimming. However, recent shortages have prompted debate regarding equitable access – raising questions about who should receive this treatment.